natgillin/translations-raw huggingface dataset:
a light chain human kappa subgroup 1 consensus framework sequence having a substitution at position 4 and/or position 47, optionally M4L and/or L47F; and/or 
okvir sekvence jakog lanca sadrži supstituciju na poziciji 48, 67, 69, 71, 73 i/ili 78, opcijski V481, F67A, I69F, R71A, N73T i/ili L78A; i/ili
A is chosen from the series consisting of C(R1) and N; 
A se bira iz skupine koju čine C(R') i N;
To a 2 L three-necked flask, set up with a mechanical stirring, containing AlCl3 (85.661 g; 642.42 mmol) under N2, 4-hexylbenzene (IVb) (104.25 g; 642.42 mmnol) was added in one portion at room temperature. 
U tikvicu s tri vrata i mehaničkom mješalicom od 2 L koja sadrži AICI3 (85,661 g; 642,42 mmol) pod N,, odjedanput se minuta bez hlađenja ukapavanjem doda (4-bromofenil)acetil klorid (IIIa) (125,000 g; 535,35 mmol).
40% to 50% by weight of a pharmaceutically acceptable lipid selected from monoglycerides of caprylic and capric fatty acids; diglycerides of caprylic and capric fatty acids, and mixtures thereof; 
do 50 masenih % farmaceutski prihvatljivog lipida odabranog od monoglicerida kapriličnih i kapričnih masnih kiselina; diglicerida kapriličnih i kapričnih masnih kiselina, te njihovih mješavina;
the heavy chain comprises an amino acid sequences represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129 or a fragnent thereof. A hybridoma capable of producing the antibody of any one of claims 1 to 20. A conjugate comprising an antibody of any one of claims 1 to 20 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 135 i varijabilno područje lakog lanca koji ima aminokiselinsku sekvencu od SEQ ID NO: 142 naznačeno time da navedena nukleinska kiselina kodira polipeptid, poželjno protutijelo, koje je sposobno vezivati se za CLD18A2 ali ne za CLD18A1 i nakon vezanja za CLD18A2 posreduje u uništavanju stanica koje eksprimiraju CLD18A2 od strane T stanica.
The herbicidal composition of claim 2 wherein monoethanolamine is added to an aqueous dispersion of clopyralid until the pH reaches a value of 5 to 6. 
Herbicidni pripravak u skladu s patentnim zahtjevom 2, naznačen time što se monoetanolamin dodaje u vodenu disperziju klopiralida dok pH ne dođe do vrijednosti od 5 do 6.
In one aspect the present invention provides compounds of formula (I) having a pKi comprised between 7 and 8. 
"E ' naznačen time što je međuprodukt u dobivanju spoja formule (I) u skladu s patentnim zahtjevom 8.
A variable speed control 43 for pump motor 42 of pump 40 can be set to control rate of pumping action of pump 40. 
HR P20060161 T3 Regulator 43 promjenljive brzine za motor 42 pumpe 40 može se podesiti da regulira brzinu pumpanja pumpe 40.
If no errors are detected, telegrams TG1, TG2, TG3, TG4 at the four outputs OUT1a, OUT2a, OUT3a, OUT4a of demultiplexer circuit 12a are transmitted via optoisolator 17 to transmission stage 5 to control the respective beacons. 
Ako nisu detcktiranc nikakve greške, telegrami TG1, TG2, TG3, TG4 kod četiri izlaza OUT1a, OUT2a, OUT3a, OUT4a, demultipleksnog komunikacijskog kruga 12a se prenose putem optoizolatora 17 prema prijenosnom podsklopu 5 radi upravljanja odnosnim balizama,
The process according to claim 7, wherein one aliphatic carboxylic acid is stearic acid and the other one is selected from the group consisting of octanoic acid, myristic acid, palmitic acid, arachidic acid, behenic acid and lignoceric acid. 
Postupak prema zahtjevu 7, gdje je jedna alifatska karboksilna kiselina stearinska kiselina i druga se izabire iz grupe koja obuhvaća oktansku kiselinu, miristinsku kiselinu, palmitinsku kiselinu, arahidonsku kiselinu, behensku kiselinu i lignocerinsku kiselinu.
The insole of claim 14, wherein the sole comprises a first material of relatively lower compressive resistance or density forming the arch region sandwiched between second or second and third materials of relatively higher compressive resistance or density. 
pribavljanje regije luka (5) od prvog materijala relativno niske kompresivne otpornosti ili gustoće; pribavljanje frontalne regije/regije za prste (4) i regije za petu (6) od drugog ili drugog i trećeg materijala relativno većih kompresivnih otpornosti ili gustoća;
The isolated antibody according to any one of claims 1 to 6, wherein said antibody is the monoclonal antibody DC8E8, wherein DC8E8 is an antibody produced by the hybridoma deposited under American Type Culture Collection Patent Deposit N° PTA-11994. 
Izolirano antitijelo prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time da je rečeno antitijelo monoklonalno antitijelo DC8E8, pri čemu je DC8E8 antitijelo proizvedeno od hibridoma pohranjenog u American Type Culture Collection Patent Deposit br. PTA-11994.
The composition of claim 8 wherein the excipient is a C4-C22 fatty acid. 
Kompozicija prema patentnom zahtjevu 13, naznačena time što je inertni punitelj Cg-Cya masna kiselina.
A candle stand (40) as claimed in claim 12 wherein the catching means (48) is filled with a non-flammable liquid in use. 
Stalak za svijeće (40) sukladno Zahtjevu 12 pri čemu su sredstva za zahvaćanje (48) punjena nezapaljivom tekućinom u uporabi.
The building section of claim 1, wherein the at least one substantially vertical structural column includes a first substantially vertical structural column and a second substantially vertical structural column coupled to the first structural column, wherein the first structural truss panel is coupled to the first structural column and the second structural truss panel is coupled to the second structural column, and wherein loads placed on the first structural truss panel are laterally transferred to the first structural column and loads placed on the second structural truss panel are laterally transferred to the second structural column such that the transferred loads are vertically transferred between the first and second structural columns. 
Postupak za izgradnju zgrade, naznačen time da sadrži: pričvršćivanje prve konstrukcijske rešetkaste ploče (20), navedena prva konstrukcijska rešetkasta ploča je konstrukcijska ploča kako je definirano u zahtjevu 1, na prvi konstrukcijski stup; pričvršćivanje drugog konstrukcijskog stupa okomito izravno na prvi konstrukcijski stup; i, pričvršćivanje druge konstrukcijske rešetkaste ploče (20) na drugi konstrukcijski stup tako da je druga konstrukcijska rešetkasta ploča okomito iznad prve konstrukcijske rešetkaste ploče, tako da postoji zazor između prve i druge konstrukcijske rešetkaste ploče (20), te tako da se okomito trenutno 1 stalno opterećenje i bočno opterećenje prenose bočno na prvi i drugi konstrukcijski stup i zatim okomito između prvog i drugog stupa umjesto na okomitu konstrukcijsku rešetkastu ploču na konstrukcijsku rešetkastu ploču.
The integrated circuit according to claim 1, wherein the remaining bit(s) are MSBs (Most Significant Bits) of the resource allocation information, and the defined value is zero. 
Uređaj za prijenos prema zahtjevu 1 ili 2, naznačen time da su preostali bi(ovi) MSB-ovi, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
According to one particular embodiment of the invention, the cationic amino acids are added to said AlOOH/HBsAg complex before the mixing with the Hib antigen. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time da se u navedeni A&OOH/HBsAg kompleks prije miješanja s Hib antigenom dodaju kationske aminokiseline.
Method for producing a laminated product, for example a building panel, preferably a floor panel (P), wherein the method comprising the steps of: 
Metoda za proizvodnju laminiranog proizvoda, na primjer građevinskog panela, poželjno podnog panela (P), gdje metoda sadrži korake:
wherein said liquid pharmaceutical composition is formulated in the form of a nasal spray or nasal drops. The method of claim 1, wherein said animal is a mammal. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pripravak formuliran kao tekuća formulacija u obliku nazalnog spreja ili nazalnih kapi.
% and preferably from 49 to 58 vol. 
% i poželjno od 49 do 58 vol.
The engraving of said indicia is preferably performed by using ablation tools selected from the group comprising mechanical ablation tools, gaseous or liquid jet ablation tools, and laser ablation tools. 
Poželjno se graviranje navedene oznake vrši alatima za graviranje odabranim iz skupine koju čine mehanički alati za graviranje, alati za graviranje plinskim mlazom ili mlazom tekućine i laserski alati za graviranje.
(c1) an antigen-binding site comprising an L chain CDR1, 2, and 3 amino acid sequences of SEQ ID NOs: 138, 139, and 140 (L chain CDR of L2), respectively; 
(cl) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 213 od SEQ ID NO: 138, 139 odnosno 140 (L-lanac CDR- područja od L2);
As further shown in Figure 22, the resulting filtrate solution went directly to the reaction to remove the TBDMS from the 2'-hydroxyl using the TBAF method, described above to obtain formula 10 and formula 11 from formula 6 and formula 7 respectively; 150µL of the reagent was added directly to the filtrate and stirred at room temperature for four hours. 
Kao što je dalje prikazano na slici 22, nastala otopina filtrata išla je direktno u reakciju da bi uklonila TBDMS iz 2'-hidroksila koristeći TBAF postupak, koji je opisan u gornjem tekstu da bi se dobila formula 10 odnosno formula 11 iz formule 6 i formule 7; 150 uL reagensa je bilo dodano direktno u filtrat i miješano na sobnoj temperaturi četiri sata.
Process according to paragraph 22, wherein the amine of formula Z is reacted with a compound of formula I wherein R is (C1-C12)alkyl. 
Postupak prema zahtjevu 8, naznačen time, da amin formule Z reagira sa spojem formule I, gdje R je (Ci-C12) alkil, pri čemu se amin formule Z poželjno upotrebljava u količini od 1 do 5 ekvivalenata.
Another aspect of the invention is a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula I in a pharmaceutically acceptable carrier. 
Farmaceutska smjesa, naznačena time, što sadrži spoj iz zahtjeva 1, u farmaceutski prihvatljivom nosaču.
Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant. 
Pripravci za raspršivanje za lokalnu isporuku inhalacijom u pluća mogu se pripraviti, primjerice, kao vodene otopine ili suspenzije ili u obliku aerosola koji se isporučuju iz spremnika pod tlakom, poput inhalatora s odmjerenom dozom uporabom prikladnog tekućeg potisnog sredstva.
Male and female beagle dogs 6-48 months of age are dosed orally via capsule with a compound of formula I. A range of doses is selected in an effort to determine a maximum tolerated dose and dose limiting toxicity. 
Mužjacima i ženkama pasa zečara starim 6-48 mjeseci oralno je, u kapsulama, doziran spoj formule I. Raspon doza odabran je tako da se odredi maksimalna podnošljiva doza i toksičnost koja ograničuje dozu.
m is 1 or 2, in free form or in salt form, and, where possible, in acid addition salt form. 
Rs je vodik ili hidroksi; i mjelili2, u slobodnom obliku ili u obliku soli, i, gdje je to moguće, u obliku kiselinske adicijske soli, kao vaniloid antagonista.
A vaccine comprising a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response that the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections. 
16. Cjepivo koje sadrži rekombinantni stafilokokni faktor grudanja A (CIfA) prema SEQ ID No. 1 ili sekvenci s barem 85%, poželjno barem 95% identičnosti sekvence u odnosu na SEQ ID No. 1 ili njegov fragment koji obuhvaća barem aminokiselinske ostatke 221 do 531 fibrmogen vezujuće regije (Regija A), s barem jednom supstitucijom ili delecijom aminokiselinskog ostatka na aminokiselinskom ostatku Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 i/ili Val527 da se dobije rekombinantni fibrinogen vezujući protein sa smanjenom sposobnosti ili bez sposobnosti nekovalentnog vezanja fibrinogena što će stimulirati veći imuni odgovor od divljeg tipa CIfA proteina, za uporabu u liječenju ili prevenciji stafilokoknih infekcija.
The immunogenic composition of any preceding claim wherein the at least two further bacterial saccharide(s) are conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT, and protein D. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
A process for the preparation a compound of claim 1, which comprises: for a compound of Formula I wherein A is NR11R12, coupling a corresponding compound having the formula II wherein L1 represents a leaving atom or group, with a compound having the formula HNR11R12, using a palladium (II) catalyst and a ligand in the presence of a base; or 
(a) za spoj formule I gdje A je NR'"R'", spajanje odgovarajućeg spoja formule II gdje L! predstavlja odlazeći atom ili skupinu, sa spojem formule HNR''R'*, uporabom paladij (II) katalizatora i liganda u prisutnosti baze; ili (b) reakciju spoja formule III
accordingly change the duration of the predetermined time (TD) so as the active load (50) absorbs from the candidate signal (Sc) said predetermined amount of energy (Ev). 
- odgovarajuću promjenu trajanja zadanog vremena (Tp) tako da aktivni teret (50) apsorbira iz kandidatnog signala (S.) navedenu zadanu količinu energije (E,).
A pharmaceutical oral dosage from comprising 
Farmaceutski proizvod koji sadrži:
Inhibition of proliferation was expressed as an IC50 value. This was determined by calculation of the concentration of compound that was required to give 50% inhibition of proliferation. 
Inhibicija proliferacije izražena je kao ICs, vrijednost, koja je određena izračunavanjem koncentracije spoja koja je potrebna za 50%-tnu ihibiciju proliferacije.
receiving modulated data pseudo-streams (9c,9d) through respective transmission channels (Ch#1... 
- > prijema moduliranih pseudo-tokova (9c,9d) podataka preko odgovarajućih prijenosnih kanala (Ch#1...
Apparatus as in claim 1, characterized in that each phase sub-module (34R, 34S, 34T) is connected with a star connection and the star centers of the individual power phase sub-modules (34R, 34S, 34T) are connected to each other to a neutral (N). 
Uređaj prema patentnom zahtjevu 1, naznačen time što je svaki od faznih pod-modula (34R, 34S, 34T) spojen sa zvjezdastim spojem i zvijezda je središte pojedinačnih pod-modula (34R, 34S, 34T) međusobno spojenih na nulu (N).
The aqueous solution was washed with n-hexane (500 ml) and the remaining aqueous phase was adjusted to pH10 with 0.88 ammonia solution. 
Vodena otopina se pere s n-heksanom (500 ml) i preostala vodena faza se podesi na pH 10 s 0,88 otopinom amonijaka.
Remove the plate from the incubator and put it at −20° C. until the immunoassay to determine the quantity of IFN-Y present in the cell supernatant is performed. 
- < Odstrani pločicu iz inkubatora te je ostavi na -20%C sve do početka imuno-testa za određivanje kvantiteta prisutnog INF-y u staničnom supernatantu.
The compound for use according to claim 13, wherein the disease is rheumatoid arthritis, multiple sclerosis and psoriasis. 
Uporaba prema patentnom zahtjevu 11, pri čemu je bolest reumatoidni artritis, multipla skleroza ili psorijaza.
The pharmaceutical composition of claim 8 for use according to claim 8 further comprising one or more neuroleptic agents selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant. 
Farmaceutski sastav prema zahtjevu 8 za uporabu prema zahtjevu 8 koji nadalje sadrži jedan ili više neuroleptičkih agensa izabranih iz sertindola, olanzapina, risperidona, kvetiapina, aripiprazola, haloperidola, klozapina, ziprasidona i osanetanta.
a layer of second hydrophobic material coated on the particle in an amount of 2% to 30% by weight, based on the weight of the particle. The pharmaceutical oral dosage form according to claim 1, wherein the layer of second hydrophobic material is coated on the particle in an amount of 2% to 30% by weight, based on the weight of the particle. 
pokrivanje najmanje dijela čestica sa slojem koji sadrži drugi hidrofobni materijal tako da matriks i sloj odvajaju opioidni antagonist u čistom obliku za doziranje, drugi hidrofobni materijal u količini od oko 5% do oko 30% težine čestica,
rotating the cable spool (37; 137) about an axis of the housing (23; 123) of the fiber optic enclosure until a desired length of the first fiber optic cable (22; 122) is paid out; 
Postupak izvlačenja optičkog kabela odmotavanjem (22, 122) iz kutije sa optičkim kabelom prema Zahtjevu 1, gdje je kućište (23, 123) postavljeno na zid.
The process of clause 9, wherein the hydrogen chloride exiting the reaction zone contains 1,1,3-trichloropropene or carbon tetrachloride or both 1,1,3-trichloropropene and carbon tetrachloride and 1,1,3-trichloropropene or carbon tetrachloride or both 1,1,3-trichloropropene and carbon tetrachloride are recycled into the reaction zone via the condensing zone. 
Postupak iz patentnog zahtjeva 9, pri čemu klorovodik koji izlazi iz reakcijske zone sadrži 1,1,3-triklorpropen ili ugljikov tetraklorid ili oboje 1,1,3-triklorpropen i ugljikov tetraklorid i 1,1,3-triklorpropen ili ugljikov tetraklorid ili oboje 1,1,3-triklorpropen i ugljikov tetraklorid se recikliraju u reakcijsku zonu putem zone kondenzacije.
In one embodiment the linker is attached to sulphydryl residues of the anti-TF antibody obtained by (partial) reduction of the anti-TF antibody. 
Konjugat protutijela s lijekom prema bilo kojem od prethodnih zahtjeva, naznačen time, da je skupina za povezivanje vezana za sulfhidrilne ostatke anti-TF protutijela dobivenog (parcijalnom) redukcijom anti-TF protutijela.
adding heating and reducing agents; characterized in that at least part of the heating and/or reducing agents is replaced by Li-ion batteries containing one or more of metallic Fe, metallic Al, and carbon. 
- < dodavanje sredstava za zagrijavanje i redukcijskih sredstava; karakteristično je da je najmanje jedan dio sredstava za zagrijavanje i/ili redukcijskih sredstava zamijenjen litijionskim baterijama koje sadrže jedan ili više metala željeza, aluminija i ugljika.
is hydrogen, hydrocarbyl or substituted hydrocarbyl; is 
R.2 je vodik, hidrokarbil ili supstituirani hidrokarbil;
is hydrogen or w-hydroxyalkyl; and X is CH or N, as well as pharmaceutically acceptable salts and polymorphs of said compounds and hydrates of the compounds of formula I and of their salts and mannitol as stabilizer. 
je vodik ili w-hidroksialkil; i X je CH ili N, kao i farmaceutski prihvatljive soli i polimorfi navedenih spojeva i hidrata spojeva formule I i njihovih soli i manitol kao stabilizator.
Another instance describes the method wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof. Another instance describess the method wherein the condition is gout. 
Spoj formule (I) kao što je utvrđeno u patentnim zahtjevima 1-9 za uporabu sukladno patentnom zahtjevu 10, pri čemu, stanje je giht, rekurentni napad gihta, gihtni artritis, hiperurikemija, hipertenzija, kardiovaskularnu bolest, koronarna bolest srca, Lesch-Nyhan-ov sindrom, Kelley-Seegmiller-ov sindrom, bolest bubrega, kamenac u bubregu, insuficijencija bubrega, inflamacija zgloba, artritis, urolitijaza, plumbizam, hiperparatiroidizam, psorijaza, sarkoidoza, deficijencija hipoksantin-guanin fosforiboziltransferaze (HPRT) ili njihova kombinacija.
The use of one of claims 1 through 3, wherein said avermectin compound is in a concentration range from about 0.05% to about 3.0% (w/w). 
Uporaba prema jednom od zahtjeva 1 do 3, naznačena time da je navedeni spoj avermektina u koncentraciji u rasponu od oko 0.05% do oko 3.0% (tež./tež.).
The transfer vehicle of the invention is a liposomal vesicle, to facilitate the transfer of a nucleic acid to target cells and tissues. 
Nosač transfera prema bilo kojem od zahtjeva 2 do 7, naznačen time što nosač transfera inkapsulira nukleinsku kiselinu ili protein.
a part of liquid steel is uninterruptedly or cyclically discharged from the steel bath of the electric arc furnace (10); and wherein from the thermic energy included in the hot process-exhaust (furnace top 20) of the electric arc furnace (10), electric energy is, by means of power generation (30, 31, 32), generated during a melting process cycle; 
dio tekućeg čelika se bez prekidanja 1li ciklično odstranjuje iz čelične kupke 1z elektrolučne peći (10); te se time - > proizvodi električna energija iz toplinske energije koja je uključena u procesuiranju vrućih ispušnih plinova kroz ispušni uređaj (vrh peći 20) od elektrolučne peći (10), pomoću generatora struje (30, 31, 32), za vrijeme ciklusa postupka taljenja; naznačen time, da -
an antisense oligomer which consists of a nucleotide sequence having deletion, substitution, insertion and/or addition of 1 to 3 nucleotides in the nucleotide sequence of SEQ ID NO: 1 or 2, and has an activity to cause skipping of the 51st exon in the human dystrophin gene; and 
antisensni oligomer sastavljen od nukleotidne sekvence koja ima deleciju, supstituciju, inserciju i/ili adiciju od 1 do 3 nukleotida u nukleotidnoj sekvenci SEQ ID NO: 1 ili 2, i ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu; i
A candle holder (10) in accordance with any one of clauses 1 to 3 wherein the inward most point of the tapered portion (16c) of the sides (16) defines a single aperture (15). 
Aranžman sa svijećnjakom sukladno Zahtjevu 1 ili 2 pri čemu je najuži dio suženog dijela (16c) stranica (16) određuje jedini otvor (15).
The formulation as defined in Claim 3 in the form of a capsule filled with stock granulation selected from the group consisting of 2.5 milligram and 10 milligram stock granulation comprising: 
Formulacija kako je definirana u patentnom zahtjevu 1 u obliku kapsule ispunjene s temeljnom granulacijom, te kapsula sadrži količinu dapagliflozin propilen glikol hidrata koja je ekvivalentna 2,5 mg ili 10 mg dapagliflozina, te temeljna granulacija sadrži: